You B, Anderson C, Cecere SC, Carrot A, et al. Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial. Gynecol Oncol 2025;197:66-73.
PMID: 40286540